Investors are noticing a significant rise in the stock price of Cardiol Therapeutics Inc Class A.
Cardiol Therapeutics Inc Class A (CRDL.TO) has seen its stock increase by 2.92% today, closing at CA$1.76. This uptick comes as interest grows around the company’s recent developments and ongoing clinical studies.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$202.88M
52W high
$2.33
52W low
$1.23
1W change
+5.39%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 240.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+240.9% Upside
Current Price
C$1.76
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
55.4%
Annualized
90-Day Vol
59.6%
Annualized
Trend (90d)
-14.1%
Annualized drift
90d Mean
C$1.67
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.73 | C$1.43 – C$2.10 |
| 60 trading days | C$1.70 | C$1.30 – C$2.23 |
| 90 trading days | C$1.67 | C$1.20 – C$2.33 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The increase in Cardiol's stock price shows rising investor confidence, likely driven by recent positive news about its clinical trials.
Cardiol's stock rises 2.92% today
With a market cap of CA$202.88 million, Cardiol's stock is attracting attention from investors looking for opportunities in the biotech sector.
Bull case
The release of Cardiol's Phase II study results in respected journals has boosted investor optimism about its potential treatments. This could lead to higher market demand and a rise in stock prices.
Bear case
Even with today’s gains, Cardiol faces challenges due to inconsistent revenue and ongoing clinical risks that could impact its long-term stock performance.
Advertisement
Recent Developments Fueling Investor Interest
Cardiol Therapeutics has recently gained attention after publishing its Phase II MAvERIC study results in the Journal of the American Heart Association. This study demonstrates the effectiveness of CardiolRx™ in treating recurrent pericarditis, which may enhance the company’s credibility and draw in more investors.
Market Reaction and Future Outlook
The positive movement in Cardiol's stock today suggests growing investor confidence. However, potential shareholders should stay cautious, as the biotech sector can be volatile, influenced by clinical trial results and regulatory approvals. For more insights, check out our detailed analysis on Cardiol Therapeutics.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
